Oxford BioDynamics PLC Grant of Indian patent for EpiSwitch platform (9014E)
15 February 2018 - 12:11AM
UK Regulatory
TIDMOBD
RNS Number : 9014E
Oxford BioDynamics PLC
14 February 2018
14 February 2018
Oxford BioDynamics Plc
("OBD" or the "Company" and, together with its subsidiaries, the
"Group")
Oxford BioDynamics announces grant of Indian patent for its
proprietary technology platform, EpiSwitch(TM)
Oxford BioDynamics Plc ("OBD" or the "Company"), a biotechnology
company focused on the discovery and development of epigenetic
biomarkers based on regulatory genome architecture, for use within
the pharmaceutical and biotechnology industry, today announces the
grant of a key patent in India by the Office of the Controller
General of Patents Designs and Trademarks covering EpiSwitch(TM),
the Company's novel technology platform.
The Indian patent, number 290615, covers OBD's proprietary
EpiSwitch(TM) technology designs for high resolution discovery and
monitoring of regulatory conditional chromosome conformation
signatures, as part of the regulatory architecture of the genome.
As a biomarker modality, chromosome conformations have been shown
to deliver highly informative stratifications of complex patient
phenotypes, assist in better disease understanding and target
identifications, and show high concordance with complex genetic and
gene expression profiles. Predictive and prognostic stratifications
developed by OBD on the basis of its proprietary EpiSwitch(TM)
technology already offer significant improvements in patient
stratifications, de-risking of drug discovery and development, and
upgraded regulatory and market protection.
This patent will further extend coverage of Oxford BioDynamics'
proprietary technology platform, EpiSwitch(TM), into the
increasingly important Indian market. Counterparts to this patent
have already been granted in the USA, Europe, China, Japan,
Australia, Hong Kong, New Zealand, Singapore and South Africa.
Christian Hoyer Millar, CEO of Oxford BioDynamics,
commented:
"We are delighted to announce the grant of this patent covering
the use of EpiSwitch(TM) in this growing market. The grant of this
patent in India further strengthens our global intellectual
property portfolio as we position the Company for future growth. We
believe EpiSwitch(TM) is a valuable and leading industry solution
capable of characterising structural modifications to genome
architecture that have a profound effect on health."
-ENDS-
For further details please contact:
Oxford BioDynamics Plc +44 (0)1865 518910
Christian Hoyer Millar,
CEO
Paul Stockdale, CFO
Shore Capital +44 (0)20 7408 4090
Broker and Nominated Adviser
Stephane Auton
Edward Mansfield
FTI Consulting +44 (0)20 3727 1000
Financial Public Relations
Adviser
Brett Pollard
Natalie Garland-Collins
Notes for Editors
About Oxford BioDynamics Plc
Oxford BioDynamics Plc (AIM: OBD) ("Oxford BioDynamics") is a
biotechnology company focused on the discovery and development of
epigenetic biomarkers for use within the pharmaceutical and
biotechnology industry.
The Company's award-winning, proprietary technology platform,
EpiSwitch(TM), aims to accelerate the drug discovery and
development process, improve the success rate of therapeutic
product development and take advantage of the increasing importance
of personalised medicine.
In particular, EpiSwitch(TM) can reduce time to market, failure
rates and the costs at every stage of drug discovery. Additionally,
the technology provides significant insights into disease
mechanisms for drug discovery and product re--positioning
programmes, and enables the personalisation of therapeutics for
patients in the context of challenging pricing environments where
improved clinical outcomes are critical.
Oxford BioDynamics is headquartered in the UK, and listed on the
London Stock Exchange's AIM under the ticker "OBD". For more
information please visit www.oxfordbiodynamics.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCSFUFDLFASESE
(END) Dow Jones Newswires
February 14, 2018 08:11 ET (13:11 GMT)
Oxford Biodynamics (LSE:OBD)
Historical Stock Chart
From May 2024 to May 2024
Oxford Biodynamics (LSE:OBD)
Historical Stock Chart
From May 2023 to May 2024